Entereg

Entereg is a brand name of alvimopan, approved by the FDA in the following formulation(s):

ENTEREG (alvimopan - capsule; oral)

• 
  Manufacturer: ADOLOR
  
  Approval date: May 20, 2008
  
  Strength(s): 12MG ^[RLD]

Has a generic version of Entereg been approved?

No. There is currently no therapeutically equivalent version of Entereg available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Entereg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Peripherally selective piperidine carboxylate opioid antagonists
  Patent 5,250,542
  Issued: October 5, 1993
  Inventor(s): Cantrell; Buddy E. & Zimmerman; Dennis M.
  Assignee(s): Eli Lilly and Company
  3,4,4-trisubstitutedpiperidinyl-N-alkylcarboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.
  
  Patent expiration dates:
  
  
  • March 29, 2016
    
    ✓ 
    Patent use: A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
  Patent 5,434,171
  Issued: July 18, 1995
  Inventor(s): Frank; Scott A. & Prather; Douglas E. & Ward; Jeffrey A. & Werner; John A.
  Assignee(s): Eli Lilly and Company
  This invention relates to a process for preparing certain 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates, intermediates, and congeners. Finally, the invention provides new 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates with formulations and methods for using the compounds.
  
  Patent expiration dates:
  
  
  • December 8, 2013
    
    ✓ 
    Patent use: A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Methods for the treatment and prevention of ileus
  Patent 6,469,030
  Issued: October 22, 2002
  Inventor(s): John J.; Farrar & Peter J.; Schied & William K.; Schmidt & Randall L.; Carpenter
  Assignee(s): Adolor Corporation
  Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
  
  Patent expiration dates:
  
  
  • November 29, 2020
    
    ✓ 
    Patent use: A METHOD OF TREATING OR PREVENTING ILEUS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 20, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Entereg Consumer Information (Drugs.com)
• Entereg Consumer Information (Wolters Kluwer)
• Entereg Consumer Information (Cerner Multum)
• Entereg Advanced Consumer Information (Micromedex)
• Entereg AHFS DI Monographs (ASHP)
• Alvimopan Consumer Information (Wolters Kluwer)
• Alvimopan Consumer Information (Cerner Multum)
• Alvimopan Advanced Consumer Information (Micromedex)
• Alvimopan AHFS DI Monographs (ASHP)